Today's Rundown Former FDA chief Gottlieb has dire warnings about hitting the brakes on social distancing measures Need-to-know drugs in testing to treat COVID-19: New rundown Moderna's COVID-19 vaccine could reach healthcare workers this fall Scangos' Vir Biotechnology to test COVID-19 antibody 'in the summer' Biopharma roundup: Gilead, Mylan to give up antiviral exclusivity, ADA still on Healthcare roundup: N.Y. has enough PPE for now; Companies reopen manufacturing plans for critical supplies Gilead asks FDA to rescind remdesivir orphan drug tag after public backlash Hospitals get $100B in massive stimulus deal as facilities face COVID-19 Mayo Clinic, Amazon, others launch collaboration to increase COVID-19 testing, vaccine development FDA to allow COVID-19 treatments with blood from survivors A tale of 2 meetings: Amid pandemic, ASCO moves online while ADA plows ahead CVS Health eyes adding drive-thru COVID-19 testing sites, waiving early prescription refill limits Biohaven embraces digital to keep migraine launch on track despite COVID-19 White House working on platform to track patient outcomes for off-label COVID-19 drugs: NYT Featured Story | | | Wednesday, March 25, 2020 Hard-hit coronavirus "hot spots" like New York City are two to three weeks away from hitting peak COVID-19 cases, according to former federal official Scott Gottlieb, M.D. Many other cities and states could be two weeks behind. |
|
|---|
|
Top Stories Wednesday, March 25, 2020 Drugmakers of all sizes are on the hunt for a possible therapeutic to deploy in the coronavirus crisis. One option? Evaluating older meds to determine whether they can be repurposed as a possible treatment for COVID-19. Here are all the latest options. Wednesday, March 25, 2020 Although Moderna’s COVID-19 vaccine is at least a year away from a widespread rollout, the company may provide the vaccine to a few people, which could include healthcare workers, as early as this fall. It could do so under an emergency use provision from the FDA. Wednesday, March 25, 2020 When Vir Biotechnology won the Fierce 15 award a few years back, infectious disease work was something of an outlier in life science R&D. But the company was adamant it was a clear and present danger to the world and one that needed addressing. Wednesday, March 25, 2020 Gilead and Mylan aim to hand back their FDA-granted marketing exclusivity for potential COVID-19 treatments, while the WHO and others detail a list of 14 repurposed drugs currently being tested in clinical trials. In Chicago, ASCO aims to take its annual meeting virtual, but the ADA says its June meeting is still on. Wednesday, March 25, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Wednesday, March 25, 2020 Gilead Sciences' investigational antiviral drug remdesivir has been saddled with high hopes as drugmakers search for a possible COVID-19 treatment. But after the FDA made the controversial decision to name remdesivir an orphan drug—a tag that comes with years of market exclusivity—Gilead bowed to critics' outrage and asked for an out. Wednesday, March 25, 2020 Hospitals and community health centers will get $130 billion in a $2 trillion economic stimulus package to help meet the skyrocketing increases of COVID-19 cases. Wednesday, March 25, 2020 The industry coalition plans to crowdsource capabilities from healthcare organizations, technology companies, non-profits, academia, and startups to provide a focused response to the coronavirus outbreak. Wednesday, March 25, 2020 The FDA unlocked the use of convalescent plasma—derived from the donated blood of people that have recovered from COVID-19 and which may contain helpful antibodies—as an investigational treatment for patients with severe cases of the disease. Wednesday, March 25, 2020 ASCO attendees, you can cancel the ultra-pricey hotel reservations, close your browser tabs on that Chicago restaurant research and let next year be the year you finally invest in more sensible shoes for trekking around McCormick Place: It’s not happening this year. But ADA-goers? You’re going to want to hold off on that. Wednesday, March 25, 2020 Healthcare giant CVS Health wants to play a big role in combating the coronavirus outbreak even its retail locations are hit with shortages of gloves and masks, CEO Larry Merlo said Tuesday. Wednesday, March 25, 2020 Biohaven only won FDA approval for its new migraine drug one month ago, but a lot has changed around the world since then. Amid the COVID-19 pandemic, the company is embracing digital communications to keep the rollout on track despite social distancing measures. Wednesday, March 25, 2020 As President Donald Trump continues to tout malaria drug chloroquine as a potential COVID-19 treatment—despite wait-and-see advice from health officials—the White House is preparing to roll out a platform to promote the drugs and track patients’ progress, The New York Times reports. | 